Why mice don't get cancer of the retina

May 02, 2006

Humans are more susceptible to developing the eye cancer retinoblastoma than mice because, unlike humans, mice can compensate for the loss of activity of a gene critical to normal retinal development , according to results of a study by investigators at St. Jude Children's Research Hospital. The study, published today in the open access journal BMC Biology, explains why humans with a defective copy of the Retinoblastoma gene RB1 are at high risk of developing cancer of the retina, or retinoblastoma, whereas mice with a similar genetic profile do not develop the cancer.

Stacy Donovan and Brett Schweers from St Jude Children's Research Hospital in Memphis, USA and colleagues from St Jude's and from the University of Tennessee Health Science Center in Memphis, studied the expression of the Retinoblastoma proteins Rb (RB1 in humans), p107 and p130 throughout the development of mouse and human retinae, using molecular amplification and immunolabelling techniques.

Donovan et al. find that p107, Rb and p130 are expressed at different stages in the developing mouse retina, with p107 expressed first and Rb and 130 expressed during the late stages of development. The authors show that, in mutant mouse embryos that do not express Rb at all, the levels of p107 are much higher than in wild-type embryos at the same stage in development. The reverse situation is observed in mutant embryos that do not express p107. This suggests that Rb and p107 compensate for each other in retinal progenitor cells and prevent the deregulated proliferation of the cells that leads to retinoblastoma. By contrast, RB1 is the main protein expressed during retinal development in humans. The protein p107 is only slightly expressed during development and cannot compensate for the lack of RB1, which leads to retinoblastoma.
-end-
Article:
Compensation by tumor suppressor genes during retinal development in mice and humans
Stacy Donovan, Brett Schweers, Rodrigo Martins, Dianna Johnson and Michael A Dyer
BMC Biology 2006, (in press)

http://www.biomedcentral.com/bmcbiol/

BioMed Central

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.